With 43% stake, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) seems to have captured institutional investors' interest [Yahoo! Finance]
Y-mAbs Therapeutics, Inc. (YMAB)
Last y-mabs therapeutics, inc. earnings: 11/13 04:01 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
The top 9 shareholders own 53% of the company Insiders have been selling lately If you want to know who really controls Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB ), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the company with 43% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait. Let's delve deeper into each type of owner of Y-mAbs Therapeutics, beginning with the chart below. See our latest analysis for Y-mAbs Therapeutics What Does The Institutional Ownership Tell Us About Y-mAbs Therapeutics? Many institutions measure their performance against an in
Show less
Read more
Impact Snapshot
Event Time:
YMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
YMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
YMAB alerts
High impacting Y-mAbs Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
YMAB
News
- Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial OfficerGlobeNewswire
- Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) is now covered by analysts at Truist Financial Co.. They set a "buy" rating and a $21.00 price target on the stock.MarketBeat
- Y-MABS SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of the Company’s Long-Term Shareholders and Encourages Investors to Contact the FirmAccesswire
- Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting [Yahoo! Finance]Yahoo! Finance
YMAB
Earnings
- 5/7/24 - Miss
YMAB
Sec Filings
- 7/1/24 - Form 8-K
- 6/28/24 - Form 8-K
- 6/13/24 - Form 4
- YMAB's page on the SEC website